Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.

Autor:	Morganti AG; Radiation Oncology Unit, Department of Experimental, Diagnostic & Specialty Medicine - DIMES, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy., Cellini F; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy., Mignogna S; General Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Padula GD; Cancer Research Consortium of West Michigan (CRCWM), Michigan State University, MI, USA., Caravatta L; Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Deodato F; Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Picardi V; Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Macchia G; Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Cilla S; Medical Physics Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Buwenge M; Radiation Oncology Unit - Fondazione di Ricerca e Cura 'Giovanni Paolo II', Campobasso, Italy., Di Lullo L; Oncology Department, General Hospital, Isernia, Italy., Gambacorta MA; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy., Balducci M; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy., Mattiucci GC; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy., Autorino R; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy., Valentini V; Radiation Oncology Department - Gemelli ART, Policlinico Universitario 'A Gemelli', Università Cattolica del Sacro Cuore, Rome, Italy.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2016 Mar; Vol. 12 (6), pp. 779-87. Date of Electronic Publication: 2016 Feb 01.
DOI:	10.2217/fon.15.350
Abstrakt:	Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Primary Objective: raising the clinical complete response rate from 5 to 25%. Secondary Objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu